Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaBest Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseMolecular pathways: trafficking of metabolic resources in the tumor microenvironmentAsparaginase pharmacokinetics and implications of therapeutic drug monitoringHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaStructural and Kinetic Characterization of Guinea Pig l -Asparaginase Type IIICrystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding sitePharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyRecent new drug approvals. Part 1: drugs with pediatric indicationsChemical metabolic inhibitors for the treatment of blood-borne cancersComparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.Glutamine addiction: a new therapeutic target in cancerSuccessful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginasePharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing propertiesDepletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.Cancer metabolism: current perspectives and future directions.Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli.In search of druggable targets for GBM amino acid metabolism.De novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy.Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia.L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutAsparaginase-associated toxicity in children with acute lymphoblastic leukemia.Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginaseUse of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.First-line treatment of acute lymphoblastic leukemia with pegasparaginase.Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.Peg-asparaginase for acute lymphoblastic leukemia.Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.Metabolic alterations in cancer cells and therapeutic implications.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Asparaginase-associated pancreatitis in children.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.Therapeutic strategies impacting cancer cell glutamine metabolism.
P2860
Q26738640-F2A7AB9D-5665-4159-BD62-C23EE6970C06Q26784116-C4CE18B8-B69E-4E9E-80EA-4FEF8E24C16DQ26825620-028E1D65-6170-4A1F-BD62-BB1D59CFF987Q27026476-D660CB06-796F-4C75-9576-44DF8AFE84E2Q27026952-C3D5816D-DF4E-4BF9-8038-79E552760051Q27682506-AD424788-AC92-4F26-B9BB-71E616275FB8Q27694569-5F8BF5EE-A896-4936-9A9D-6CA9E8F87A5AQ28083449-311F8ABE-5115-4D13-A731-E867F87E72A9Q28709081-776BDDED-475F-418B-B0EF-332C1414AE0AQ28822335-2846224A-922D-4AF6-B25E-889DEE87697FQ33701864-6EEB5CDE-8C84-4C6D-B20C-7A1272B31510Q34050094-985281A7-3327-4A17-AB4D-AF7E2F715395Q34064049-61CE2DB9-989D-4B68-8ADF-48F957B903DFQ34221738-F24F2B68-7107-43E7-9CB5-3DB8E697795AQ34551046-86086CA2-DB13-4DDB-A278-35C72359F04FQ34580270-F2B8A545-2226-48A8-AD55-3570D9BDD86DQ35638576-D961DF00-0BE6-498A-A513-339000F1CC33Q35723836-3EA6953F-D593-4585-9B90-A41AB35CAE31Q35989408-548085FE-D1F6-474B-9E81-BAAB7017597AQ36038158-A85D1A06-D028-42EE-9599-DFD0DC73FC25Q36293108-571C8A77-66CC-4266-82DE-C03D0B4097FAQ36405822-20B2851C-2AC0-4AC3-AD86-1B97BF7F8857Q36463010-8560A80F-A1AC-4853-BFFE-34E01D797289Q36619115-2D80E6C9-506C-4D5C-AD1D-96F1F4736866Q36649984-492F0155-5F83-4104-A8A8-0A054CEAB0AAQ36678136-8AA5985E-6BBE-448A-A5CC-F3176CCDA6B3Q36762608-E3421A4B-B35F-4159-B71C-53A3F02253D3Q36918761-F80ED40A-1BC2-48FB-B1E1-FB7070925037Q37046992-26A23ED0-DC9C-42BB-BB87-A6E4529EA978Q37241386-9E02C7B2-3F2C-4859-9307-6408AB01D444Q37522294-01EE5271-6470-4564-A57D-77546719675DQ37586935-394DDC16-1D5B-47AE-8D49-A32098B42DA4Q37612333-7BD1EDC2-BE22-4A98-BF5F-196BC029EFDBQ37719558-577740A4-08C4-4BCF-8C2A-D89825891960Q37730054-D2947F42-1355-46F1-A4D1-1E53C01630CCQ37908233-338201B9-2778-4A31-9790-B0889A40C107Q37914185-A0C138A4-B2CB-4E22-BDC7-C3B874BC8DA2Q38036389-37D65ADF-E5C4-46D1-B0C5-A87DA83A7217Q38040418-68B13F84-9264-479F-BAE2-9A2955D3A782Q38139096-EACB4794-A842-4CD1-9898-BC1F62940945
P2860
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacokinetic/pharmacodynami ...... ecommendations for the future.
@ast
Pharmacokinetic/pharmacodynami ...... ecommendations for the future.
@en
type
label
Pharmacokinetic/pharmacodynami ...... ecommendations for the future.
@ast
Pharmacokinetic/pharmacodynami ...... ecommendations for the future.
@en
prefLabel
Pharmacokinetic/pharmacodynami ...... ecommendations for the future.
@ast
Pharmacokinetic/pharmacodynami ...... ecommendations for the future.
@en
P1476
Pharmacokinetic/pharmacodynami ...... ecommendations for the future.
@en
P2093
Eduard H Panosyan
Vassilios I Avramis
P304
P356
10.2165/00003088-200544040-00003
P577
2005-01-01T00:00:00Z
P6179
1022517387